NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$2.7b

NewAmsterdam Pharma Valuation

Is NAMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: NAMS ($22.49) is trading below our estimate of future cash flow value ($132.33)

Significantly Below Future Cash Flow Value: NAMS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAMS?

Key metric: As NAMS barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NAMS. This is calculated by dividing NAMS's market cap by their current book value.
What is NAMS's PB Ratio?
PB Ratio4.3x
BookUS$631.42m
Market CapUS$2.69b

Price to Book Ratio vs Peers

How does NAMS's PB Ratio compare to its peers?

The above table shows the PB ratio for NAMS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
ZLAB Zai Lab
4.8x33.68%US$2.9b
CDNA CareDx
6.5x-20.30%US$2.8b
AUPH Aurinia Pharmaceuticals
3.7x-4.79%US$2.2b
VCYT Veracyte
2.3x5.51%US$3.2b
NAMS NewAmsterdam Pharma
4.3x65.24%US$2.7b

Price-To-Book vs Peers: NAMS is good value based on its Price-To-Book Ratio (4.3x) compared to the peer average (4.3x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does NAMS's PB Ratio compare vs other companies in the US Biotechs Industry?

63 CompaniesPrice / BookEstimated GrowthMarket Cap
CNTN Canton Strategic Holdings
0.4xn/aUS$183.27m
FRMM Forum Markets
0.5x127.09%US$61.51m
IMA ImageneBio
0.4x-32.04%US$55.51m
ALVR AlloVir
0.4xn/aUS$48.46m
NAMS 4.3xIndustry Avg. 2.2xNo. of Companies80PB0246810+
63 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NAMS is expensive based on its Price-To-Book Ratio (4.3x) compared to the US Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is NAMS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAMS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NAMS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAMS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$22.49
US$50.92
+126.39%
11.12%US$59.27US$37.80n/a15
Sep ’27US$24.92
US$51.55
+106.84%
11.18%US$60.22US$38.14n/a15
Aug ’27US$27.79
US$51.42
+85.05%
11.94%US$60.79US$37.24n/a15
Jul ’27US$35.17
US$49.61
+41.06%
11.22%US$58.44US$36.87n/a14
Jun ’27US$31.79
US$50.16
+57.78%
11.41%US$59.50US$37.54n/a14
May ’27US$28.43
US$49.88
+75.44%
12.72%US$61.63US$38.08n/a14
Apr ’27US$32.81
US$48.98
+49.29%
12.72%US$60.53US$37.41n/a14
Mar ’27US$35.46
US$48.96
+38.06%
11.73%US$59.80US$38.04n/a13
Feb ’27US$31.12
US$48.97
+57.35%
12.31%US$61.17US$37.75n/a13
Jan ’27US$35.08
US$47.61
+35.72%
12.85%US$61.02US$37.40n/a13
Dec ’26US$39.61
US$46.64
+17.74%
12.98%US$60.29US$36.95n/a13
Nov ’26US$37.95
US$42.24
+11.30%
12.65%US$51.91US$29.95n/a13
Oct ’26US$29.36
US$40.80
+38.95%
11.62%US$45.33US$27.18n/a12
Sep ’26US$24.05
US$40.46
+68.25%
11.63%US$44.92US$26.94US$24.9212
Aug ’26US$21.28
US$41.07
+92.99%
13.90%US$51.71US$26.60US$27.7912
Jul ’26US$18.22
US$43.61
+139.35%
8.95%US$52.97US$37.99US$35.1711
Jun ’26US$18.11
US$42.55
+134.94%
10.46%US$52.09US$37.03US$31.798
May ’26US$20.03
US$46.96
+134.44%
12.32%US$56.86US$38.95US$28.439
Apr ’26US$18.38
US$44.96
+144.60%
11.93%US$53.91US$36.93US$32.819
Mar ’26US$21.00
US$43.52
+107.26%
13.08%US$51.98US$35.39US$35.469
Feb ’26US$22.29
US$44.25
+98.50%
11.95%US$52.29US$35.26US$31.129
Jan ’26US$25.70
US$43.36
+68.72%
15.45%US$52.47US$29.08US$35.089
Dec ’25US$19.85
US$38.45
+93.68%
17.87%US$49.82US$29.29US$39.618
Nov ’25US$17.82
US$37.61
+111.06%
17.40%US$49.88US$29.26US$37.958
Oct ’25US$17.29
US$38.44
+122.32%
17.54%US$51.14US$30.00US$29.368
Sep ’25US$16.42
US$38.79
+136.21%
17.10%US$51.35US$30.50US$24.058
US$50.92
Fair Value
55.8% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 07:28
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 20 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Conor MacKayBMO Capital Markets Equity Research
Steven SeedhouseCantor Fitzgerald & Co.
Geoffrey MeachamCitigroup Inc